TSTao Sun

Tao Sun

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Tao Sun has a total of 99 co-authors. Here are the top co-authors by number of shared publications:

  • Chunyan Ji

    Department of Hematology, Qilu Hospital of Shandong University, Jinan, China

    14 shared publications
  • Mingying Li

    Department of Hematology Qilu Hospital of Shandong University Jinan Shandong Province 250012 China

    10 shared publications
  • Jingjing Ye

    Department of Hematology Qilu Hospital Cheeloo College of Medicine Shandong University Jinan 250012 P. R. China

    9 shared publications
  • Yuan Xia

    Department of Hematology, Qilu Hospital of Shandong University, Cheeloo College of Medicine, Shandong University

    8 shared publications
  • Dongmei Wang

    Department of Hematology, Qilu Hospital of Shandong University, Jinan, China

    6 shared publications
  • Guosheng Li

    Department of Hematology Qilu Hospital of Shandong University Jinan Shandong Province 250012 China

    5 shared publications

Latest Publications

  • Open Access

    m6A demethylase–driven reprogramming of leukemia-associated macrophages predicts improved outcomes in acute myeloid leukemia

    by Zhiyu Shi, Yuan Xia, Mingyue Zhang, Ying Peng, Yun An, Qingjun Zhu, Tao Sun

    Background: N6-methyladenosine (m 6 A) is a dynamic mRNA modification influencing transcript fate and cellular identity, especially in cancer. While oncogenic roles of m 6 A regulators in AML cells are known, their impact on the leukemic immune microenvironment is unclear. Methods: In this study, we constructed a single-cell atlas of macrophages in AML by integrating publicly available scRNA-seq datasets from 129 patient cohorts. Data were batch-corrected using Seurat and Harmony. Macrophage subpopulations were identified, and the expression and activity of 29 m 6 A regulators were analyzed. Pseudotime analysis (Monocle3), cell–cell communication (CellChat), and pathway enrichment (Metascape) analyses were performed to explore m 6 A-related functional programs. Survival analysis was conducted using Kaplan–Meier curves. RT-qPCR was used to verify the correlation between m 6 A regulatory molecules and prognosis. Results: Our findings indicated that m 6 A regulators are associated with macrophage fate. Writer-high macrophages showed enhanced proliferation and differentiation, maintaining monocyte-like features. Eraser-high macrophages remodeled macrophage function toward an M1-like, pro-inflammatory and antigen-presenting state. Reader-high macrophages drove macrophages toward an immunosuppressive, M2-like phenotype, while m 6 A-deficient cells exhibit features of functional exhaustion. Survival analysis based on bulk RNA-seq data further revealed that m 6 A-regulated macrophage profiles were associated with distinct prognostic stratification in AML patients. RT-qPCR analysis of macrophages isolated from clinical AML samples further validated these findings, showing that patients with favorable prognosis exhibited significantly higher expression levels of erasers compared to those with poor prognosis. Conclusion: These results highlight m 6 A system’s role in macrophage reprogramming and suggest that targeting m 6 A regulators in macrophages may serve as a potential basis for prognostic stratification and a promising therapeutic strategy in AML.

  • Open Access

    Artificial intelligence derived virtual oncology

    by Chunyi Lyu, Dongbo Yao, Fangjing Yin, Zhaonian Liu, Bingqiang Liu, Huixian Ma, Tao Sun

    Tumors are dynamic multicellular ecosystems in which heterogeneity, evolution, and cross-scale interactions remain major barriers to precision oncology. Although multiple technological advances have improved tumor characterization, they remain largely static and descriptive, limiting their ability to capture state transitions, treatment-induced remodeling, and evolving intercellular communication. Artificial intelligence virtual cell (AIVC) provides a foundation for modeling cellular states, perturbation responses, and functional outputs from multimodal data. We extend this concept to artificial intelligence virtual oncology (AIVO), a framework designed to reconstruct multicellular communication, coordinated evolution, and system-level remodeling among tumor, immune, and stromal compartments. This review summarizes the conceptual basis, construction strategies, and emerging applications of this progression from AIVC to AIVO in tumor diagnosis, dynamic monitoring, treatment response prediction, and drug screening. We further discuss key challenges in data integration, interpretability, patient-specific calibration, and clinical validation. Grounded in AIVC-based modeling, we propose AIVO as an emerging framework for multimodal integration, dynamic modeling, and decision support in future oncology.


  • Open Access

    Anti-gallbladder cancer activities and toxicity studies of glycyrrhetinic acid derivative as a novel PPARγ agonist

    by Min Liu, Haizhang Ma, Gaozhong Xiong, Mei Qi, Yuan Xia, Yunxue Zhao, Chunyan Ji, Juan Sun, Tao Sun

    Introduction: Chemotherapy remains the mainstay treatment for gallbladder cancer; however, its therapeutic efficacy is limited by poor chemosensitivity. Therefore, identifying more effective treatment strategies is essential for improving patient prognosis. In this study, we evaluated the antitumor activity of a novel PPARγ agonist, PG-4c, in gallbladder cancer and assessed its in vivo toxicity. Methods: Human gallbladder cancer cells were treated with PG-4c to examine its effects on the cell cycle, apoptosis, invasion, migration, and intracellular apoptotic signaling. A xenograft tumor model was used to assess the antitumor efficacy of PG-4c in vivo. Toxicity associated with PG-4c was evaluated in both mice and zebrafish. Results: PG-4c exhibited stronger anticancer activity than the standard chemotherapeutic agent gemcitabine. Its antitumor mechanisms involved inducing cell-cycle arrest, apoptosis, and necrosis through elevated intracellular reactive oxygen species levels and activation of cleaved caspase-3. PG-4c also impaired actin assembly, thereby inhibiting migration and invasion. In vivo, PG-4c significantly suppressed tumor growth in both zebrafish and mouse xenograft models. Notably, PG-4c demonstrated lower toxicity than the traditional PPARγ agonist pioglitazone, as supported by animal toxicity assays. Discussion: Our findings suggest that PG-4c holds strong potential as an effective chemotherapeutic candidate for gallbladder cancer. Given that PPARγ agonists are clinically approved drugs for dyslipidemia and diabetes, this class of agents may represent a promising new therapeutic approach for gallbladder cancer management.

  • Open Access

    Liquid-liquid phase separation of ZHX2 protects DLBCL cells against ferroptosis through induction of SLC3A2

    by Juan Zhang, Dongmei Wang, Mengfan Luan, Xiaomin Liu, Nana Wang, Xue Sheng, Shuying Li, Boya Li, Tao Sun, Daoxin Ma, et al.

    Diffuse large B-cell lymphoma (DLBCL), the most common B-cell non-Hodgkin lymphoma (B-NHL), is characterized by strong aggression, high heterogeneity, and poor prognosis. Consequently, there is an urgent need to identify crucial therapeutic targets. Here, we found that the transcription factor zinc-finger and homeobox 2 (ZHX2) was highly expressed in DLBCL. Subsequently, ZHX2 was proven to be critical for promoting DLBCL cell proliferation by inhibiting ferroptosis. Mechanistically, ZHX2 bound to the promoter region of the solute carrier family 3-member 2 (SLC3A2) gene through liquid-liquid phase separation (LLPS) and activated its function to negatively regulate ferroptosis. Furthermore, we constructed lipid nanoparticles ZHX2-siRNA@LNP targeting DLBCL, which effectively inhibited the growth of the tumors in vivo. In summary, our study indicated that the LLPS of ZHX2 protected DLBCL against ferroptosis through induction of SLC3A2, and disturbing it with ZHX2-siRNA@LNP could significantly repress DLBCL, providing a promising therapeutic strategy for DLBCL.


  • Open Access

    Adiponectin Assists Thrombopoietic Agents in ITP Treatment by Enhancing Myosin‐9/Rab6A‐Mediated Trafficking of c‐Mpl in MKs

    by Xin Zhao, Huixian Ma, Guosheng Li, Jilong Xiao, Zhiyu Shi, Mingying Li, Xinguang Liu, Tao Sun, Chunyan Ji

    Immune thrombocytopenia (ITP) is an autoimmune disorder characterized by accelerated platelet destruction and defective platelet production. The thrombopoietin (TPO)‐activated c‐Mpl signaling pathway has been proven to promote megakaryocyte differentiation and platelet production and thus has significant value in the clinical treatment of ITP. However, individual differences and unsustainable responses limit the clinical application of c‐Mpl agonists. The cell membrane distribution of c‐Mpl is crucial for the cell response to c‐Mpl agonists. In the present study, this is observed that the distribution of c‐Mpl on the megakaryocyte membrane is significantly reduced in ITP patients. The reduction is more severe in refractory patients. Then, this is verified that the membrane trafficking of c‐Mpl is mediated by the Myosin‐9/Rab6A complex, and demonstrates that the stability of this complex depends on Rab6A‐GTPase. Furthermore, this is found that adiponectin promotes the membrane localization of c‐Mpl by increasing the expression of Rab6A GEFs. Finally, this is revealed that adiponectin can assist thrombopoietic agents in the treatment of ITP mice. The results clarify the c‐Mpl distribution defects in the cell membrane and the corresponding c‐Mpl membrane transport mechanisms in megakaryocytes of ITP, providing new insights to improve the clinical efficacy of thrombopoietic agents for ITP patients.


  • Open Access

    A ROS‐Responsive Dual‐Targeting Drug Nanocarrier Serving as a GSI Synergist and Ferroptosis Sensitizer for T‐Cell Acute Lymphoblastic Leukemia

    by Ruinan Jia, Yang Liu, Jilong Xiao, Yuan Xia, Xin Zhao, Huixian Ma, Jingjing Ye, Zhiyue Zhang, Tao Sun, Chunyan Ji

    T‐cell acute lymphoblastic leukemia (T‐ALL) is a highly aggressive hematological malignancy for which targeted therapies remain underdeveloped. Oncogenic mutations in Notch1 occur in up to 75% of T‐ALL patients. Although γ‐secretase inhibitors (GSIs) can block Notch1 activation, their clinical application is limited by side effects and reduced sensitivity. Here, a self‐assembling, reactive oxygen species (ROS)‐responsive nanotherapeutic strategy—PHD/G‐NPs—co‐loaded with GSI and controlled released dihydroartemisinin (DHA), and modified with a CD38 antibody is reported. The CD38 antibody specifically targets T‐ALL cells, while GSI selectively inhibits Notch1, resulting in a dual‐targeting approach. GSI is released first, inhibiting Notch1 activation and inducing the death of a subset of T‐ALL cells. To eliminate semi‐quiescent T‐ALL cells that escape initial therapy by elevating ROS levels, a ROS‐sensitive DHA delivery system is employed to enhance ferroptosis and boost GSI efficacy. After elucidating the mechanism of action of PHD/G‐NPs in T‐ALL cells, PHD/G‐NPs are combined with αPD‐1, which triggers an anti‐tumor immune response in vivo. This dual‐targeting strategy using CD38‐modified PHD/G‐NPs enables controlled drug release, enhances ferroptosis, mitigates GSI‐induced gastrointestinal toxicity, and improves therapeutic efficacy. This nanomedical approach offers a novel strategy for targeted T‐ALL treatment.


  • Open Access

    Polymorphisms in immunosuppression-related genes are associated with AML

    by Mingying Li, Jingjing Ye, Mengyuan Chang, Lei Feng, Tingting Liu, Di Zhang, Yuyan Wu, Yuechan Ma, Guangqiang Meng, Chunyan Ji, et al.

    Background: Acute myeloid leukemia (AML) is a hematologic malignancy with poor overall survival (OS). The immunosuppressive microenvironment significantly impacts AML development and chemoresistance. Despite new immunotherapeutic strategies entering standard clinical care for various tumors, progress in AML remains poor. Multi-omics analyses, such as single-cell transcriptomics, have revealed many potential new targets to improve AML prognosis from an immunological perspective.Methods: DNA from 307 AML patients and 316 healthy individuals were extracted. We detected nine single nucleotide polymorphisms (SNPs) in five immunosuppression-related genes (CIITA, CD200, CD163, MRC1 and LILRB4) in these samples. SNP genotyping was performed on the MassARRAY platform. We then analyzed the relationship between these SNPs and AML susceptibility, treatment response, and prognosis.Results: Our findings indicated that rs4883263 in the CD163 gene is a protective factor for AML susceptibility and chromosomal karyotype abnormalities. Additionally, rs4883263 in CD163 was related to low PLT count at diagnosis, while rs2272022 in CD200 was protective against low PLT count. rs4780335 in CIITA was associated with high WBC count at diagnosis and worse OS. Furthermore, rs1048801 in LILRB4 was linked to worse AML treatment response, lower OS, and may be an independent prognostic risk factor for AML. Lastly, expressions of CD163, CIITA, LILRB4, and CD200 were higher in AML patients than that in normal controls.Conclusions: Our findings on SNP associations in AML immunosuppression-related genes provide important reference points for predicting treatment outcomes in AML patients.


  • Open Access

    Homodimer-mediated phosphorylation of C/EBPα-p42 S16 modulates acute myeloid leukaemia differentiation through liquid-liquid phase separation

    by Dongmei Wang, Tao Sun, Yuan Xia, Zhe Zhao, Xue Sheng, Shuying Li, Yuechan Ma, Mingying Li, Xiuhua Su, Fan Zhang, et al.

    CCAAT/enhancer binding protein α (C/EBPα) regulates myeloid differentiation, and its dysregulation contributes to acute myeloid leukaemia (AML) progress. Clarifying its functional implementation mechanism is of great significance for its further clinical application. Here, we show that C/EBPα regulates AML cell differentiation through liquid-liquid phase separation (LLPS), which can be disrupted by C/EBPα-p30. Considering that C/EBPα-p30 inhibits the functions of C/EBPα through the LZ region, a small peptide TAT-LZ that could instantaneously interfere with the homodimerization of C/EBPα-p42 was constructed, and dynamic inhibition of C/EBPα phase separation was observed, demonstrating the importance of C/EBPα-p42 homodimers for its LLPS. Mechanistically, homodimerization of C/EBPα-p42 mediated its phosphorylation at the novel phosphorylation site S16, which promoted LLPS and subsequent AML cell differentiation. Finally, decreasing the endogenous C/EBPα-p30/C/EBPα-p42 ratio rescued the phase separation of C/EBPα in AML cells, which provided a new insight for the treatment of the AML.


  • Open Access

    Immune checkpoint‐related gene polymorphisms are associated with acute myeloid leukemia

    by Yuyan Wu, Mingying Li, Guangqiang Meng, Yuechan Ma, Jingjing Ye, Tao Sun, Chunyan Ji

    Background: Chemotherapy is still the standard regimen for treating acute myeloid leukemia (AML) and its disappointing efficacy requires the urgent need for new therapeutic targets. It is well known that immune response plays an increasingly significant role in the pathogenesis of AML.Methods: We detected nine single nucleotide polymorphisms (SNPs) in immune checkpoint‐related genes, including PD1, LAG3, TIM3, and TIGIT in 285 AML inpatients and 324 healthy controls. SNP genotyping was performed on the MassARRAY platform. Furthermore, we analyzed the relationship between the susceptibility and prognosis of AML and the selected SNPs.Results: Our results showed that rs2227982 and rs10204525 in PD1 were significantly associated with susceptibility to AML after false discovery rate correction. PD1 rs10204525 also showed a significant correlation with the response to chemotherapy and risk stratification of AML. Importantly, the AA genotype of PD1 (rs2227982) under the recessive model showed a negative impact on AML prognosis independently.Conclusions: Our results indicate that PD1 SNPs are important for susceptibility and prognosis in AML, which may provide a new therapeutic target for AML patients.


  • Open Access

    KLK2 single-nucleotide polymorphism rs198977 is associated with increased susceptibility and hyperleukocytosis in AML

    by Guangqiang Meng, Peng Li, Mingying Li, Yuyan Wu, Yuechan Ma, Tao Sun, Chunyan Ji

    Introduction: Acute myeloid leukemia (AML) is a heterogeneous myeloid malignancy with abnormal molecular diversity. Tissue kallikrein 2 (KLK2) is a kind of serine protease, and has a close relationship with the occurrence and development of malignant tumors. Single nucleotide polymorphism (SNP) of various genes are associated with susceptibility, treatment and survival of AML.Methods: We investigated the association of KLK2 SNPs rs198977 and rs2664155 with AML. We recruited 284 AML patients and 280 healthy controls from the Han population and genotyping KLK2 SNPs rs198977 and rs2664155 by MassARRAY system.Results: Using clinical data from AML patients and controls, including AML susceptibility, blood count, risk stratification, response to induced chemotherapy and survival, our results showed an increased risk of AML susceptibility with KLK2 rs198977 TT genotype in the recessive model. Regarding white blood cell counts in AML patients, the results showed an increased risk of hyperleukocytosis with the TT genotype of KLK2 rs198977 in a codominant model. Moreover, in the recessive model, AML with KLK2 SNPs rs198977 TT genotype had an increased risk of hyperleukocytosis. No significant correlation was found between KLK2 rs2664155 and AML.Discussion: This study suggests that KLK2 rs198977 may be an important genetic factor in the occurrence of AML and hyperleukocytosis in AML, providing a new perspective for disease progression and new therapeutic targets.